473P - Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metasta...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Colon and Rectal Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Arndt Stahler
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors A. Stahler1, S. Stintzing2, M. Urbischek3, D.P. Modest2, L. Fischer von Weikersthal4, J. Kumbrink3, V. Heinemann2, T. Kirchner3, A. Jung3
  • 1Institute Of Pathology, Klinikum der Universität München, 80337 - München/DE
  • 2Medical Dept. Iii, Klinikum der Universität München, München/DE
  • 3Institute Of Pathology, Klinikum der Universität München, München/DE
  • 4Oncology, Klinikum St. Marien Amberg, Amberg/DE



Our aim was to evaluate fibroblast growth factor 2 (FGF2) expression in cultivated CRC cell lines exposed to 5-fluorouracil (5-FU) and validate results with clinical data from mCRC patients receiving first-line chemotherapy.


5-FU IC50 was determined in CRC cell lines DLD1, LoVo, and HCT-15 applying MTT assays. mRNA expression of FGF2 was measured by RT-qPCR with HPRT as reference gene. Threshold values were determined by minimum p-value method. FGF2 expression was knocked down by sh (short hairpin) RNA in vitro. FGF receptor (FGF-R) was inhibited using Dovitinib with DMSO as control. In vitro results were were translated on the randomized FIRE1 trial (5-FU/LV/irinotecan [FUFIRI] vs. irinotecan/oxaliplatin [mIrOx] using Nanostring technology. 187 patients were included in this analysis.


48 h incubation of CRC cell lines with 5-FU showed an increase of FGF2 expression [DLD1: 1.98-fold, p 


FGF2 expression might reflect chemoresistance in CRC cell lines as a knockdown of FGF2 led to a decrease of IC50 for 5-FU in vitro. In FIRE1, high FGF2 expression was associated with lower response rate and overall survival significantly. Interfering the FGF2 system might be a modulator for acquired chemoresistance.

Clinical trial identification

Legal entity responsible for the study

Department of Medicine III, University of Munich; Institute of Pathology, University of Munich


Weigand-Bohnewand-Gravenhorst-Fond, University of Munich


All authors have declared no conflicts of interest.